Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium
Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia 2017, 31: 1391-1397. PMID: 28111463, DOI: 10.1038/leu.2017.33.Peer-Reviewed Original ResearchConceptsInternational Prognostic Scoring SystemT-MDS patientsDe novo myelodysplastic syndromePrognostic scoring systemNovo myelodysplastic syndromeMyelodysplastic syndromeT-MDSClinical outcomesScoring systemMDS Clinical Research ConsortiumClinical Research ConsortiumRisk stratification toolRisk group categoriesRisk stratification modelConventional risk stratification modelPrognostic systemPrior therapyMedian survivalIndolent courseInferior survivalMDS patientsPrognostic utilityStratification toolWorse outcomesPatients